Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974541 | 0.84 | CHRM2 (0.34) | FABP7FABP5EPHX1CHRM2CHRM4 | |
| SCHEMBL30209917 | 0.81 | CYP3A4 (0.36) | FABP7FABP5EPHX1CHRM2CHRM4 | |
| SCHEMBL30209960 | 0.79 | CYP3A4 (0.34) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL13103753 | 0.79 | EPHX1 (0.38) | EPHX1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2681392 | 0.78 | EPHX1 (0.38) | FABP7FABP5EPHX1CHRM2CHRM4 | |
| SCHEMBL9908326 | 0.77 | CYP1A2 (0.37) | CHRM2CHRM4CHRM3CYP2C19 | |
| SCHEMBL21654483 | 0.77 | CYP1A2 (0.37) | CHRM2CHRM4CHRM3CYP2C19 | |
| SCHEMBL14316058 | 0.77 | — | — | |
| SCHEMBL13103754 | 0.77 | EPHX1 (0.36) | EPHX1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13103771 | 0.76 | EPHX1 (0.36) | EPHX1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228412-A1 | PRODUCTION METHOD FOR PRODUCING DIMETHANOL COMPOUND HAVING NORBORNANE SKELETON | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228412-A1 | PRODUCTION METHOD FOR PRODUCING DIMETHANOL COMPOUND HAVING NORBORNANE SKELETON | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228412-A1 | PRODUCTION METHOD FOR PRODUCING DIMETHANOL COMPOUND HAVING NORBORNANE SKELETON | DHCR7, DBH, ADH5 | FABP7 3409/4885FABP5 3422/4885EPHX1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.